These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29557803)

  • 1. Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
    Khalid B; Mukherjee S; Ibrahimi S; Cannon T; Gilles E; Moreau A; Razaq M
    Am J Ther; 2018; 25(3):e394-e396. PubMed ID: 29557803
    [No Abstract]   [Full Text] [Related]  

  • 2. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sonidegib (Odomzo°) and extensive basal cell carcinoma.
    Prescrire Int; 2017 Jan; 26(178):14-15. PubMed ID: 30730637
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
    Khoo AB; Ali FR; Lear JT
    Curr Opin Oncol; 2016 Mar; 28(2):180-4. PubMed ID: 26780190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 6. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
    Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
    J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
    [No Abstract]   [Full Text] [Related]  

  • 9. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice.
    Yan BY; Hibler BP; Menge T; Dunn L; Ho AL; Rossi AM
    Br J Dermatol; 2019 May; 180(5):1260-1261. PubMed ID: 30693471
    [No Abstract]   [Full Text] [Related]  

  • 10. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 12. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
    Chen L; Silapunt S; Migden MR
    Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 14. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 15. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
    Powell EM; Stratton JS; Shendrik I; Blalock TW
    Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
    [No Abstract]   [Full Text] [Related]  

  • 16. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib in basal cell carcinoma.
    Amaria RN; Bowles DW; Lewis KD; Jimeno A
    Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.